Approval for Incorporation of Subsidiary in the Philippines and Investment by way of Subscription to its Equity Share Capital is attached herewith.

238/LG/SE/AUG/2026/GBSL August 14, 2026 To To The Listing Department The Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code : 509079 Scrip Symbol : GUFICBIO Subject: Approval for Incorporation of Subsidiary in the Philippines and Investment by way of Subscription to its Equity Share Capital Dear Sir/Madam, Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e. Friday, August 14, 2026, has approved the incorporation of a subsidiary in the Philippines and investment by way of subscription to the equity share capital of the proposed subsidiary, subject to completion of applicable statutory and regulatory formalities. The details required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed herewith as “Annexure A”. The meeting of the Board of Directors commenced at 5:00 p.m. and concluded at 6:10 p.m. Kindly take the same on your record. Thanking You, Yours truly, For Gufic Biosciences Limited Ami Shah Company Secretary & Compliance Officer Membership No. A39579 Encl.: As above Annexure A Sr. Particulars Details 1. Name of the entity, date & country Name of proposed entity: Gufic Philippines Inc. or of incorporation, etc such other name as may be approved by the Securities and Exchange Commission (SEC), Philippines / competent regulatory authority. Date of incorporation: The entity is proposed to be incorporated within 12 months, subject to completion of applicable statutory and regulatory formalities. Country of incorporation: Philippines. 2. Name of holding company of the Gufic Biosciences Limited will be the holding incorporated company and relation company of the proposed subsidiary. with the listed entity 3. Industry to which the entity being Pharmaceuticals incorporated belongs 4. Brief background about the entity The proposed subsidiary will undertake marketing, incorporated in terms of products / sale, distribution and other allied activities in line of business relation to the Company’s pharmaceutical products in the Philippines and facilitate the expansion of the Company’s business and presence in the Philippines, including holding and managing Intellectual Property Rights in the Philippines. 5. Brief details of any governmental or The proposed incorporation and investment are regulatory approvals required for subject to applicable statutory and regulatory the incorporation requirements, including incorporation/registration with the Securities and Exchange Commission (SEC), Philippines, applicable pharmaceutical regulatory approvals/licences and registrations, as may be applicable, and compliance with applicable foreign exchange / overseas investment regulations in India. 6. Nature of consideration - whether The investment will be made by way of cash cash consideration or share swap or subscription to the equity share capital of the any other form and details of the proposed subsidiary. same 7. Cost of subscription / price at which Investment of up to USD 250,000 (United States the shares are subscribed Dollars Two Hundred Fifty Thousand only), or its equivalent amount in Philippine Peso. 8. Percentage of shareholding / The Company proposes to hold approximately control by the listed entity and / or 99.99% of the equity share capital of the proposed number of shares allotted subsidiary. The balance equity shareholding will be held by the directors of the proposed subsidiary in accordance with the applicable laws of the Philippines. The Company will have control over the proposed subsidiary.